Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Towa Completes Deal For Pensa

Transaction Worth €329m Was Agreed In Late 2019

Executive Summary

Japan’s Towa has completed its €329m deal for the Pensa Investments generics business of Spain’s Esteve.

You may also be interested in...



Towa Recovers Domestically On The Back Of New Launches

Japan’s Towa saw 4.6% growth in domestic sales in the first nine months of FY21, on the back of new launches, as the coronavirus pandemic had only a “minor” effect on its business. But while the firm’s launch schedule for new products remains unaffected so far, the company pointed out that there may be slight delays in product development plans going ahead.

COVID-19 Alters But Doesn’t Change M&A Machine In 2020

Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.

Towa’s New Overseas Business Boosted By COVID-19 Demand

Japan’s Towa Pharmaceutical endured a mixed financial first quarter, seeing the April round of Japanese National Health Insurance pricing measures bite into domestic sales while its new overseas business thrived as COVID-19 pushed up demand.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel